Featured Tickers:
Sifting through countless of stocks in the Biotechnology industry can be tedious, and sometimes two stocks are just too similar to judge which is the better investment. If you’re on the fence about investing in Aurinia Pharmaceuticals Inc. or Zai Lab Limited because you’re not sure how they measure up, it’s important to compare them on a few factors before making your decision.
Read on to learn how Aurinia Pharmaceuticals Inc. and Zai Lab Limited compare based on key financial metrics to determine which better meets your investment needs.
About Aurinia Pharmaceuticals Inc. and Zai Lab Limited
Aurinia Pharmaceuticals Inc. is a biopharmaceutical company that engages in delivering therapies to people living with autoimmune diseases with high unmet medical needs. It offers LUPKYNIS (voclosporin), an oral therapy for the treatment of adult patients with active lupus nephritis. The company also develops AUR200, a dual inhibitor of B cell activating factor and a proliferation inducing ligand for the potential treatment of autoimmune diseases. It has a collaboration and license agreement with Otsuka Pharmaceutical Co., Ltd. The company was incorporated in 1993 and is headquartered in Edmonton, Canada.
Zai Lab Limited, a biopharmaceutical company, focuses on discovering, developing, and commercializing products that address medical conditions in the areas of oncology, immunology, neuroscience, and infectious diseases. Its commercial products include Zejula, an orally administered poly (ADP-ribose) polymerase 1/2 inhibitor for treating ovarian cancer; VYVGART, a human IgG1 antibody fragment for generalized myasthenia gravis and chronic inflammatory demyelinating polyneuropathy; NUZYRA for community-acquired bacterial pneumonia and acute bacterial skin and skin structure infections; Optune for glioblastoma multiforme; Qinlock for gastrointestinal stromal tumors; Xacduro for treating hospital-acquired and ventilator-associated bacterial pneumonia caused by a cinetobacter baumannii-calcoaceticus complex; and Augtyro for the treatment of ROS proto-oncogene 1 and non-small cell lung cancer. The company’s oncology pipeline includes bemarituzumab, tumor treating fields, tisotumab vedotin, and repotrectinib; and immunology, neuroscience, and infectious disease pipeline comprises efgartigimod and xanomeline and trospium chloride. Zai Lab Limited has license and collaboration agreements with Tesaro, Inc. to develop, manufacture, and commercialize niraparib; NovoCure Ltd. to develop and commercialize Tumor Treating Fields; Deciphera Pharmaceuticals, LLC to develop and commercialize ripretinib; Paratek Bermuda Ltd. to develop, manufacture, and commercialize omadacycline; argenx BV to develop and commercialize efgartigimod; Bristol-Myers Squibb Company to develop and commercialize tisotumab vedotin and repotrectinib; Amgen Inc. to develop and commercialize bemarituzumab; Innoviva, Inc. to develop and commercialize Sulbactam-Durlobactam; and Karuna Therapeutics, Inc. to develop and commercialize Xanomeline and trospium chloride, as well as strategic collaboration with Pfizer Inc. for sulbactam and durlobactam. The company was incorporated in 2013 and is headquartered in Pudong, China.
Latest Biotechnology and Aurinia Pharmaceuticals Inc., Zai Lab Limited Stock News
As of November 21, 2025, Aurinia Pharmaceuticals Inc. had a $2.1 billion market capitalization, compared to the Biotechnology median of $197.3 million. Aurinia Pharmaceuticals Inc.’s stock is up 74.6% in 2025, up 2.1% in the previous five trading days and up 92.87% in the past year.
Currently, Aurinia Pharmaceuticals Inc.’s price-earnings ratio is 28.5. Aurinia Pharmaceuticals Inc.’s trailing 12-month revenue is $265.8 million with a 29.3% net profit margin. Year-over-year quarterly sales growth most recently was 8.4%. Analysts expect adjusted earnings to reach $0.782 per share for the current fiscal year. Aurinia Pharmaceuticals Inc. does not currently pay a dividend.
As of November 21, 2025, Zai Lab Limited had a $2.2 billion market cap, putting it in the 58th percentile of all stocks. Zai Lab Limited’s stock is down 23.6% in 2025, down 8% in the previous five trading days and down 23.44% in the past year.
Currently, Zai Lab Limited does not have a price-earnings ratio. Zai Lab Limited’s trailing 12-month revenue is $441.6 million with a -46.8% net profit margin. Year-over-year quarterly sales growth most recently was 13.5%. Analysts expect adjusted earnings to reach $-1.614 per share for the current fiscal year. Zai Lab Limited does not currently pay a dividend.
How We Compare Aurinia Pharmaceuticals Inc. and Zai Lab Limited Stock Grades
Stock evaluation requires access to huge amounts of data and the knowledge and time to sift through it all, make sense of financial ratios, read income statements and analyze recent stock movements. AAII created A+ Investor, a robust data suite that condenses data research in an actionable and customizable way suitable for investors of all knowledge levels, to help investors streamline and work through such data.
AAII’s proprietary stock grades come with A+ Investor. These offer intuitive A‐F grades for each of five key investing factors: value, growth, momentum, earnings estimate revisions and quality. Here, we’ll take a closer look at Aurinia Pharmaceuticals Inc. and Zai Lab Limited’s stock grades to see how they measure up against one another.
Learn more about A+ Investor here!
Sign Up to Receive a Free Special Report Showing How A+ Grades Can Help You Make Smarter Investment Decisions